COVID-19 IgM/IgG Lateral Flow Assay
Hoʻolauna Huahana
ʻO Virusee® COVID-19 IgM/IgG Lateral Flow Assay kahi immunoassay kahe ʻaoʻao i hoʻohana ʻia no ka ʻike in vitro qualitative o ka novel coronavirus (SARS-CoV-2) IgM / IgG antibodies i loko o ke kanaka venipuncture i ke koko holoʻokoʻa, plasma, a me nā specimens serum.
ʻO ka novel coronavirus kahi maʻi RNA stranded hoʻokahi.ʻAʻole like me ka coronavirus i ʻike ʻia, ʻoi aku ka maʻalahi o ka heluna kanaka no ka Novel Coronavirus, a ʻoi aku ka hoʻoweliweli ʻana i ka poʻe ʻelemakule a i ʻole ka poʻe me nā maʻi kumu.ʻO IgM/IgG antibodies maikaʻi kahi hōʻailona koʻikoʻi o nā maʻi coronavirus hou.ʻO ka ʻike ʻana i nā antibodies kikoʻī coronavirus hou e kōkua i ka maʻi maʻi.
Nā hiʻohiʻona
| inoa | COVID-19 IgM/IgG Lateral Flow Assay |
| Kaʻina hana | Lateral Flow Assay |
| ʻAno laʻana | Koko, plasma, serum |
| Hōʻike | 20 ho'āʻo/kit |
| Ka manawa ʻike | 10 min |
| Nā mea ʻike | COVID-19 |
| Paʻa | Paʻa ka pahu no 1 makahiki ma 2-30 ° C |
Pōmaikaʻi
- wikiwiki
Loaʻa ka hopena i loko o 10 min - Maʻalahi
ʻIke ʻia ka hopena heluhelu, maʻalahi ke wehewehe
Kaʻina hana maʻalahi, me ka ʻole o ka hana paʻakikī
- Mālama i ke kumu kūʻai
Hiki ke lawe ʻia a mālama ʻia ka huahana ma ka lumi wela, e hōʻemi ana i nā kumukūʻai - pilikia haʻahaʻa
Ke hoʻāʻo ʻana i ka laʻana koko, e hōʻemi ana i ka pilikia o ke kaʻina hana laʻana - He kūpono no ka nānā ʻana ma ka pūnaewele, ʻaoʻao moe, outpatient
Ke kumu a me ke kumu
ʻO ka coronavirus novel, severe acute respiratory syndrome coronavirus (SARS-CoV)-2, ua ʻike ʻia ʻo ia ke kumu kumu o ka maʻi coronavirus 2019 (COVID-19).Ua kapa ʻia kēia maʻi he pilikia olakino lehulehu o ka hopohopo honua e ka World Health Organization (WHO).
Hoʻopiʻi ʻo COVID-19 i nā ʻōnaehana hanu luna a me lalo a hoʻoulu i nā hōʻailona like-flu i ka hapa nui o ka poʻe i maʻi.ʻOiai he nui nā maʻi maʻi COVID-19 e ʻike i nā hōʻailona maʻalahi wale nō, ua loaʻa i kekahi mau maʻi nā hōʻailona koʻikoʻi e alakaʻi ana i ka pōʻino nui.Ua kaupalena ʻia nā koho lapaʻau no COVID-19 a ʻo ka nui o ka make ʻana i manaʻo ʻia e ka WHO ma kahi o 2.9%.ʻOiai hiki ke loaʻa i kahi kano pale pale no COVID-19, inā ʻaʻole i hoʻokō ʻia ka pale ʻana o ka puaʻa, hiki i ka COVID-19 ke hoʻoulu i ka maʻi nui a me ka make i nā makahiki e hiki mai ana.
Ma hope o ka loaʻa ʻana o kahi maʻi, he mea maʻamau ka hoʻomohala ʻana i kahi pane antibody e kūʻē i kahi pathogen.Ma hope koke o ka maʻi (maʻamau ma hope o ka pule mua), e ulu ana kahi papa o nā antibodies i kapa ʻia ʻo immunoglobulin M (IgM), ʻoiai ʻaʻole kēia mau mea lōʻihi.Ma hope aku, ma hope o nā pule 2-4 mua ma hope o ka maʻi, hana ʻia ʻo IgG, kahi antibody lōʻihi.
Ua ʻike nā haʻawina he mau hōʻailona maikaʻi loa nā antibodies i hoʻopaʻa ʻia i ka RBD o ka maʻi mua a me ka maʻi hou, hiki i nā ana isotype ʻokoʻa ke kōkua i ka ʻokoʻa ma waena o nā maʻi hou a me nā maʻi kahiko.ʻO ka ʻike ʻana i nā antibodies IgM a me IgG e kūʻē iā SARS-CoV-2 he mea koʻikoʻi koʻikoʻi no ka loiloi ʻana i ka paʻakikī a me ka wānana o COVID-19, a me ka hoʻonui ʻana i ka pololei o ka ʻike ʻana i ka hoʻāʻo wai nuklea.
He mea nui ka ʻike ʻana o SARS-CoV-2 IgM a me IgG e hoʻoholo ai i ke ʻano o COVID-19.ʻO ka ʻike ʻana i ka waikawa nucleic i hui pū ʻia me ka antibody serum o SARS-CoV-2 ʻo ia ka mea hōʻailona ʻoihana maikaʻi loa no ka maʻi o ka maʻi SARS-CoV-2 a me ka ʻōlelo a me ka predication no ka wānana o COVID-19.
Kaʻina hoʻāʻo
ʻIke Kauoha
| Hoʻohālike | wehewehe | Code huahana |
| VMGLFA-01 | 20 hoʻāʻo/kit, hōʻano cassette | CoVMGLFA-01 |
